The estimated Net Worth of Paul J Hastings is at least $4.34 Millón dollars as of 18 June 2024. Mr Hastings owns over 1,770 units of Nkarta stock worth over $1,545,532 and over the last 13 years he sold NKTX stock worth over $1,975,097. In addition, he makes $820,101 as CEO y Pres & Director at Nkarta.
Mr has made over 32 trades of the Nkarta stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 1,770 units of NKTX stock worth $9,912 on 18 June 2024.
The largest trade he's ever made was exercising 42,738 units of Nkarta stock on 5 January 2017 worth over $61,115. On average, Mr trades about 2,997 units every 71 days since 2011. As of 18 June 2024 he still owns at least 240,737 units of Nkarta stock.
You can see the complete history of Mr Hastings stock trades at the bottom of the page.
Paul J. Hastings is the CEO, Pres & Director at Nkarta.
As the CEO y Pres & Director of Nkarta, the total compensation of Mr Hastings at Nkarta is $820,101. There are no executives at Nkarta getting paid more.
Mr Hastings is 61, he's been the CEO y Pres & Director of Nkarta since . There are no older and 5 younger executives at Nkarta.
Paul's mailing address filed with the SEC is C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani y Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta executives and other stock owners filed with the SEC include: